8-K: Vor Biopharma's Telitacicept Shines in Sjögren's Phase 3

Vor Biopharma Inc. announced positive 48-week Phase 3 clinical trial data from China for telitacicept in primary Sjögren's disease, demonstrating significant efficacy and a favorable safety profile.

Summary

• Vor Biopharma presented late-breaking 48-week Phase 3 clinical trial data from China for telitacicept in primary Sjögren's disease (pSD).
• Telitacicept demonstrated statistically significant and clinically meaningful improvement in pSD across multiple endpoints.
• At Week 24, the telitacicept 160mg group showed a -4.4 change in ESSDAI score from baseline, significantly better than -0.6 for the placebo group (P <0.0001).
• At Week 24, the telitacicept 160mg group showed a -1.9 change in ESSPRI score from baseline, significantly better than -0.4 for the placebo group (P <0.0001).
• At Week 48, the telitacicept 160mg group sustained improvement with a -4.6 change in ESSDAI score from baseline, compared to -0.4 for placebo.
• At Week 48, the telitacicept 160mg group showed a -2.56 change in ESSPRI score from baseline, compared to -0.41 for placebo.
• Nearly 90% of patients reported improvement, and physicians confirmed disease control in 3 out of 4 patients.
• 55% of patients on 160mg telitacicept achieved low disease activity (ESSDAI <5) at 48 weeks, compared to 12.2% in the placebo group.
• Telitacicept produced a clinically meaningful 12-point improvement in MFI-20 Total Score (fatigue) over 48 weeks for the 160mg group, compared to 0.0 for placebo.
• The drug demonstrated consistent reduction in IgG, IgA, IgM, and B cells, indicating a disease-modifying effect.
• Telitacicept also showed deep, sustained duration of response in generalized myasthenia gravis (gMG) with MG-ADL change from baseline of -7.5 at Week 48 and QMG change from baseline of -9.8 at Week 48.
• The safety profile was favorable and consistent over one year of therapy, with AE rates comparable to placebo and no new safety signals or opportunistic infections reported.
• Telitacicept is a TACI-Fc fusion protein providing dual BAFF/APRIL inhibition, designed to stop B cell survival and plasma cell antibody production.
• Telitacicept has 3 commercial approvals in China (SLE, RA, gMG) and 2 Biologics License Application (BLA) submissions in China (pSD, IgA Nephropathy).

Sentiment

Score: 9

Explanation: The filing presents overwhelmingly positive Phase 3 clinical trial data for telitacicept in primary Sjögren's disease, demonstrating significant efficacy across multiple endpoints and a favorable safety profile. The drug also shows strong results in generalized myasthenia gravis and has a proven track record of approvals in China, indicating strong commercial potential and a validated mechanism of action. This positions telitacicept as a potential best-in-disease and disease-modifying therapy in significant unmet medical needs.

Positives

• Statistically significant and clinically meaningful improvements in primary Sjögren's disease (pSD) as measured by ESSDAI and ESSPRI scores at both 24 and 48 weeks, with the 160mg dose showing a -4.6 ESSDAI change and -2.56 ESSPRI change at 48 weeks.
• High proportion of pSD patients (nearly 90%) reported symptom improvement, and 75.4% showed physician-confirmed disease control.
• 55% of patients on 160mg telitacicept achieved low disease activity (ESSDAI <5) at 48 weeks, significantly higher than the 12.2% in the placebo group.
• Clinically meaningful 12-point improvement in fatigue (MFI-20 Total Score) over 48 weeks for the 160mg group, addressing a critical daily symptom for patients.
• Demonstrated deep, sustained duration of response in generalized myasthenia gravis (gMG) with significant MG-ADL (-7.5 at Week 48) and QMG (-9.8 at Week 48) score reductions.
• Favorable and consistent safety profile across multiple indications and ~1,800 patients in clinical trials, with AE rates comparable to placebo and no new safety signals or opportunistic infections.
• Dual BAFF/APRIL inhibition mechanism of action (MOA) is associated with improvement across all ESSPRI domains (dryness, fatigue, pain) and consistent reduction in IgG, IgA, IgM, and B cells, suggesting disease modification.
• Telitacicept has already achieved 3 commercial approvals in China (Systemic Lupus Erythematosus, Rheumatoid Arthritis, generalized Myasthenia Gravis) and 2 BLA submissions (pSD, IgA Nephropathy), indicating a proven track record and commercial viability.
• Potential to become the first disease-modifying therapy in gMG and a best-in-disease treatment for pSD, addressing significant unmet medical needs.

Risks

• Uncertainties inherent in the initiation, completion of, and availability and timing of results from, preclinical studies and clinical trials.
• Whether preclinical data or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials.
• The uncertainty of regulatory approvals to conduct trials or to market products.
• Reliance on third parties over which Vor Bio may not always have full control.
• The availability of funding sufficient for Vor Bio's foreseeable and unforeseeable operating expenses and capital expenditure requirements.

Future Outlook

Vor Bio plans for the development and commercialization of telitacicept, aiming for it to be a best-in-disease and disease-modifying therapy in generalized myasthenia gravis (gMG) and primary Sjögren's disease (pSD). The company believes in the potential therapeutic benefits of telitacicept in various indications and its expected favorable safety profile. They also highlight significant market opportunities and addressable patient populations for telitacicept.

Management Comments

• Jean-Paul Kress, M.D., Chairman & Chief Executive Officer: "Deep, sustained duration of response over time underscores BAFF/APRIL inhibition."
• Jean-Paul Kress, M.D., Chairman & Chief Executive Officer: "Opportunity to become the first disease modifying therapy in gMG."
• Jean-Paul Kress, M.D., Chairman & Chief Executive Officer: "Clinically Meaningful, Statistically Clear Robust, dose-dependent improvements across physicianand patient-assessed outcomes."
• Jean-Paul Kress, M.D., Chairman & Chief Executive Officer: "Consistent Safety Profile No new safety signals. No opportunistic infection reported."
• Jean-Paul Kress, M.D., Chairman & Chief Executive Officer: "Telitacicept showed statistically significant and clinically meaningful improvement in pSD."
• Jean-Paul Kress, M.D., Chairman & Chief Executive Officer: "Nearly 90% of patients report improvement as physicians confirm disease control in 3 out of 4 patients."
• Dallan Murray, Chief Commercial Officer: "Telitacicept: Potential Best-In-Disease Efficacy Globally."
• Dallan Murray, Chief Commercial Officer: "Favorable safety profile – no PML, minimal infections through BAFF/APRIL modulation to regulate, not eradicate, B cells."
• Dallan Murray, Chief Commercial Officer: "Proven long term safety with 10s of thousands of commercially treated patients and ~1,800 patients treated in clinical trials."
• Dallan Murray, Chief Commercial Officer: "Dual BAFF/APRIL blockade restores B-cell balance and supports long-term disease modification."

Industry Context

Primary Sjögren's disease is one of the most common systemic autoimmune diseases globally, with an estimated ~870,000 diagnosed patients across key markets (US, EU, Japan). This market is significantly underpenetrated, lacking approved disease-modifying systemic therapies, with patients primarily managed through symptomatic treatments. Telitacicept's dual BAFF/APRIL inhibition mechanism offers a potential disease-modifying approach, addressing a critical unmet need. The rising diagnosis rates due to better awareness and testing further contribute to favorable growth drivers in this therapeutic area.

Comparison to Industry Standards

• Telitacicept's gMG results, showing an MG-ADL change from baseline of -7.5 at Week 48, are presented as competitive or superior to historical clinical data for other treatments such as Efgartigimod (-6.3), Nipocalimab (-7.5), Rozanolixizumab (-6.4), and Ravulizumab (-1.6).
• Telitacicept's pSD ESSDAI change from baseline of -4.3 (for the 160mg dose) is positioned favorably against other therapies like Efgartigimod (-3.8), Nipocalimab, Ianalumab, and Dazodalibep, suggesting high efficacy in pSD.
• The filing asserts that telitacicept meets all criteria for an ideal profile to transform Sjögren's disease treatment, including achieving a statistically significant >3-point reduction in ESSDAI, demonstrating a clean, non-cytotoxic B-cell approach with a favorable safety profile (no PML, minimal infections), providing proven long-term safety from extensive commercial use and clinical trials, and delivering disease modification through dual BAFF/APRIL blockade that restores B-cell balance.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical trial results, potential for new market approvals, and validation of the company's pipeline, suggesting future revenue growth.
• Patients (pSD & gMG): Significant positive impact due to a potential new, effective, and disease-modifying treatment option for conditions with high unmet needs, offering improved quality of life.
• Healthcare Providers: Provides a new, effective therapeutic option for managing primary Sjögren's disease and generalized myasthenia gravis, potentially shifting treatment paradigms.

Next Steps

• Oral presentation of 48-week Open-Label Extension (OLE) results for generalized myasthenia gravis (gMG) on October 29, 2025.
• Continued development and commercialization of telitacicept in various indications.
• Pursuit of regulatory approvals for primary Sjögren's disease (pSD) and IgA Nephropathy (IgAN) in China, following already submitted Biologics License Applications (BLAs).

Key Dates

Recommendation

The filing provides compelling evidence of telitacicept's efficacy and safety in a large Phase 3 trial for primary Sjögren's disease, a market with significant unmet needs. The drug's dual BAFF/APRIL mechanism is validated, and it has already secured multiple approvals in China, demonstrating commercial viability. The strong results in generalized myasthenia gravis further diversify its potential. These positive clinical outcomes, coupled with the potential for disease modification and a favorable safety profile, position Vor Biopharma for substantial growth and market penetration in autoimmune diseases. The data suggests a high likelihood of regulatory success and strong commercial uptake, making it an attractive investment.

Keywords

Telitacicept, Sjögren's Disease, Primary Sjögren's Disease, pSD, Generalized Myasthenia Gravis, gMG, BAFF/APRIL inhibitor, Clinical Trial, Phase 3, Autoimmune Disease, Biopharma, China, ESSDAI, ESSPRI, MFI-20